Last updated 2026-09-04
- Went public on NASDAQ (SLXN), Aug 2024
- Raised $175M Series F, 2021
- Raised $80M Series E, 2020
Total raised
$374.0M
Last: Public Offering 2025-09
Stage
Public
Founded
2008
Headcount
14
HQ
Modi'in-Maccabim-Re'ut, Israel
Sector
Health Tech & Life Sciences
Website ↗Registrar ID: 514207778 (Silexion Therapeutics Corp)
About
Silexion Therapeutics is a pioneering clinical-stage oncology-focused biotechnology company engaged in discovering and developing proprietary treatments for KRAS-driven cancers. The company's platform technology addresses difficult-to-treat solid tumors using RNA interference (RNAi) technology and targeted drug delivery. Their lead product candidate, SIL-204, consists of locally administered small interfering RNAs (siRNA) in an extended-release formulation for the first-line treatment of locally advanced pancreatic cancer patients combined with standard-of-care chemotherapy.
Funding history · 15 rounds · $374.0M total
17 events/rounds · $374.0M Total Funding: $332.3M in Private Equity, $45.7M in Public Equity, $2.0M in Debt
Sep 2026
Public Offering
$840K
EDGAR filing SEC-EDGAR 424B3
May 2026
PIPE
$1.0M
EDGAR filing SEC-EDGAR 8-K
Sep 2025
Public Offering
$13.2M
EDGAR filing SEC-EDGAR 8-K
Aug 2025
PIPE
$1.8M
EDGAR filing SEC-EDGAR 8-K
Aug 2025
Public Offering
$9.6M
EDGAR filing SEC-EDGAR 424B3
May 2025
Public Offering
$5.0M
EDGAR filing SEC-EDGAR 424B3
Jan 2025
Public Offering
$5.0M
EDGAR filing SEC-EDGAR 8-K
Jan 2025
PIPE
$3.3M
EDGAR filing SEC-EDGAR 8-K
Aug 2024
Debt Financing
$2.0M
EDGAR filing SEC-EDGAR 8-K
2021
F Round
$175.0M
dealroom.co
2020
E Round
$80.0M
dealroom.co
2018
D Round
$32.5M
dealroom.co
2017
C Round
$28.0M
dealroom.co
2016
B Round
$13.0M
dealroom.co
2013
Seed
$3.8M
dealroom.co
Headcount over time
14 employees (2026-09) · 1 point
Offices
Modi'in-Maccabim-Re'ut, Israel · HQ / main office
Q&A
- What is Silexion Therapeutics' primary focus?
- Silexion Therapeutics is a clinical-stage biotechnology company focused on discovering and developing proprietary RNA interference (RNAi) treatments for KRAS-driven cancers.
- When did Silexion Therapeutics become publicly traded?
- Silexion Therapeutics became publicly traded on NASDAQ in August 2024, following a business combination with Moringa Acquisition Corp.
- What is Silexion Therapeutics' lead product candidate?
- Silexion Therapeutics' lead product candidate is SIL-204, which consists of locally administered small interfering RNAs (siRNA) in an extended-release formulation for the first-line treatment of locally advanced pancreatic cancer patients.
- What was a significant funding event for Silexion Therapeutics in August 2024?
- In August 2024, Silexion Therapeutics secured $17,000,000 through Debt Financing.
- What was the amount raised in Silexion Therapeutics' Public Offering in September 2025?
- In September 2025, Silexion Therapeutics raised $6,000,000 through a Public Offering.
- What is the current employee count for Silexion Therapeutics?
- Silexion Therapeutics has 13 employees, falling within the 11-50 employee bucket.
- What strategic partnership did Silexion Therapeutics announce in September 2025?
- In September 2025, Silexion Therapeutics announced a strategic partnership with AMS Advanced Medical Services GmbH, a contract research organization (CRO), to support its upcoming Phase 2/3 clinical trials for SIL204.
- What preclinical results did Silexion Therapeutics announce in September 2025 for SIL204?
- In September 2025, Silexion Therapeutics announced positive preclinical results for SIL204, demonstrating high inhibition rates (83.5% to 99.7%) across eleven human cancer cell lines with various KRAS mutations, including the first evidence of activity in gastric cancer.
- What was a key regulatory achievement for Silexion Therapeutics in March 2026?
- In March 2026, Silexion Therapeutics received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.
- What collaboration did Silexion Therapeutics announce in December 2024?
- In December 2024, Silexion Therapeutics announced a collaboration with Evonik to develop an advanced siRNA formulation for its siRNA candidate, SIL-204, aimed at improving cancer treatment efficacy.
Team · 11
Ilan Hadar
Chairman & Chief Executive Officer
Dr. Mitchell Shirvan
Chief Scientific and Development Officer
Mirit Horenshtein Hadar
Chief Financial Officer
Racheli Gabai-Malka, PhD
VP Pharmaceutical Development
Michal Yaron
VP Regulatory Affairs
Orit Pollack Shragai
VP Clinical
Dror Abramov
Chairman of the Board
Avner Lushi
Director
Shlomo Noy
Director
Ruth Alon
Director
Meni Sofiof
Accessibility Coordinator
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Highlights
1 PatentsVerified
Tags
drug-discoverybiological-therapycanceroncologydrug-deliverypharmaceuticalscancer-therapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | silexion.com/ |
|---|
Identifiers & details
| Legal name | Silexion Therapeutics Corp |
|---|---|
| Former names | Silenseed |
| Founded | 2008-11 |
| Employees (exact) | 14 |
| Market cap | $6.0M |
| Status reason | Public on NASDAQ on Aug, 2024; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2024-08 | NASDAQ | SLXN | |
| Public Offering | 2025-09 | NASDAQ | SLXN | $6.0M |
Radar intelligence
Patents
| EPO | 3 |
|---|
Web history (Wayback)
| Domain | silexion.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514207778 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2008-11-30 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 1 — other (1) |
| Registered address | דרך אבא הלל 12 רמת גן |
Recent registry events
| Date | Event |
|---|---|
| 2025-12-24 | עדכון כתובת ו/או מען דיגיטלי |